Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCLAIM-Lp(a) phase 3 study of lepodisiran in adults with elevated lipoprotein(a) and established ASCVD or high first cardiovascular event risk
CTR20242182Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lepodisiran in atherosclerotic disease, cardiac morbidity, sponsored by Eli Lilly and Company. Started Jul 2024; status: active.
02
Drugs
lepodisiran
03
Conditions
atherosclerotic diseasecardiac morbidity
Beyond the preview
Go deeper on CTR20242182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242182.